



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

ENSAT registry-based randomized clinical trials for adrenocortical carcinoma

This is the author's manuscript
Original Citation:
Availability:
This version is available http://hdl.handle.net/2318/1769103 since 2021-07-12T13:48:27Z
Published version:
DOI:10.1530/EJE-20-0800
Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

- 1 ENSAT Registry-Based Randomized Clinical Trials for Adrenocortical Carcinoma
- 2
- 3 Joakim Crona¹, Eric Baudin², Massimo Terzolo³, Alexandra Chrisoulidou⁴, Anna Angelousi⁵, Cristina L Ronchi^{6,7}, Cristina Lamas Oliveira⁸, Els J. M. Nieveen van Dijkum⁹, Filippo Ceccato¹⁰, Francoise 4 5 Borson-Chazot¹¹, Giuseppe Reimondo¹², Guido AM Tiberi¹³, Hester Ettaieb¹⁴, Andreas Kiriakopoulos¹⁵, Canu Letizia¹⁶, Darko Kastelan¹⁷, Esthr Osher¹⁸, Eugenia Yiannakopoulou¹⁹, Giorgio Arnaldi²⁰, 6 Guillaume Assié^{21,22}, Isabel Paiva²³, Isabelle Bourdeau²⁴, John Newell-Price²⁵, Karolina M. Nowak²⁶, M. 7 8 Tous Romero²⁷, Maria Cristina De Martino²⁸, Maria João Bugalho²⁹, Mark Sherlock³⁰, Marie-Christine 9 Vantyghem³¹, Michael Conall Dennedy³², Paula Loli³³, Patrice Rodien³⁴, Richard Feelders³⁵, Ronald de Krijger^{36,37}, Sam Van Slycke³⁸, Simon Aylwin³⁹, Valentina Morelli⁴⁰, Laurent Vroonen⁴¹, Zulfiya 10 Shafigullina⁴², Irina Bancos⁴³, Małgorzata Trofimiuk-Müldner⁴⁴, Marcus Quinkler⁴⁵, Michaela Luconi¹⁶, 11 Matthias Kroiss^{7,46}, Mitsuhide Naruse⁴⁷, Peter Igaz^{48,49}, Radu Mihai⁵⁰, Silvia Della Casa⁵¹, Alfredo 12
- 13 Berruti⁵², Martin Fassnacht^{7,46}, and Felix Beuschlein^{53,54}
- 14

15 Author affiliations:

- 1) Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- 2) Gustave Roussy, Université Paris-Saclay, Département d'imagerie, Service d'oncologie
- endocrinienne, Villejuif, France
- 3) Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital, Orbassano, Italv
- 4) Department of Endocrinology, Theagenio Cancer Hospital, Thessaloniki, Greece
- 5) National and Kapodistrian University of Athens, 1st Department of Internal Medicine, Unit of Endocrinology, Laiko hospital, Athens, Greece
- 6) Institute of Metabolism and System Research, University of Birmingham, Birmingham, United Kingdom
- 7) Division of Endocrinology and Diabetes, University Hospital of Würzburg, Würzburg, Germany
- 8) Endocrinology Department. Complejo Hospitalario Universitario de Albacete, Albacete, Spain
- 9) Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 10) Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy 11) Hospices Civils de Lyon, Fédération d'Endocrinologie, Université Claude Bernard Lyon 1, Lyon,
- France
- 12) Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy
- 13) Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia at ASST Spedali Civili, Brescia, Italy,
- 14) Department of Internal Medicine, Division of Endocrinology, Maxima Medical Center,
- Eindhoven/Veldhoven, The Netherlands 15) 5th Surgical Clinic, "Evgenidion Hospital" National and Kapodistrian University of Athens School of Medicine, Athens, Greece
- 16) Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
- 17) Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia
- 18) Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center Israel, Sackler Faculty of Medicine, Tel Aviv University, Israel
- 19) Department of Biomedical Sciences, Faculty of Health Sciences, University of West Attica, Athens, Greece
- 20) Division of Endocrinology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy
- 21) Université de Paris, Institut Cochin, INSERM, CNRS, Paris, France
- 22) Endocrinology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France

23) Department os Endocrinology, Diabetes and Metabolism Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal 24) Division of Endocrinology, Department of Medicine, Research Center, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Québec, Canada. 25) Department of Oncology and Metabolism The Medical School University of Sheffield, Sheffield, United Kinadom 26) Department of Endocrinology, Centre of Postgraduate Medical Education, Bielanski Hospital, Warsaw, Poland 27) UGC Endocrinología v Nutrición, Hospital Universitario Virgen Macarena, Seville, Spain 28) Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy. 29) Serviço de Endocrinologia, Diabetes e Metabolismo, CHULN and Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal 30) Department of Endocrinology, Beaumont Hospital and the Royal College of Surgeons in Ireland, Dublin, Ireland 31) Endocrinology, Diabetology, Metabolism and Nutrition Department, Lille University Hospital, Lille, France 32) Dept. of Endocrinology & Diabetes Mellitus, c/o Dept. of Medicine, Clinical Sciences Institute, National University of Ireland, Galway, Galway, Ireland 33) Ospedale Niguarda Ca' Granda, Endocrinology, Napoli, Italy 34) Service d'endocrinologie diabétologie et nutrition, CHU d'Angers, Angers cedex 9, France 35) Erasmus Medical Center, Department of Internal Medicine, Division of Endocrinology, Rotterdam, The Netherlands. 36) Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 37) University Medical Center, Department of Pathology, Utrecht, The Netherlands 38) General and Endocrine Surgery, OLV Hospital Aalst, Aalst, Belgium 39) King's College Hospital, London, United Kingdom 40) Endocrinology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy 41) Department of Endocrinology, Centre hospitalier universitaire de Liège, Liege, Belgium 42) North-Western Medical University named after I.I.Mechnikov, Endocrinology Department, Saint-Petersburg, Russia 43) Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, United States 44) Department of Endocrinology, Jagiellonian University Medical College, Kraków, Poland 45) Endocrinology in Charlottenburg, Berlin, Germany 46) Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany 47) Endocrine Center, Ijinkai Takeda General Hospital and Clinical Research Institute of Endocrinology and Metabolism, NHO Kyoto Medical Center, Kyoto, Japan 48) 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary 49) MTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary 50) Churchill Cancer Centre, Department of Endocrine Surgery, Oxford University, Oxford, United Kinadom 51) Endocrinology Department, Gemelli Polyclinic Foundation, Catholic University, Rome 52) Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy. 47 48 53) Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland 49 50 51 54) Department of Endocrinology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany 52 Abbreviated title: ENSAT registry-based trials 53 Key terms: adrenocortical cancer, registry-based trials, chemotherapy, biomarker, 54 clinical trials 55 Total words: 2806 56 Number of figures and tables: 3 57 Abbreviations: ACC, adrenocortical carcinoma, ENSAT, European Network for the 58 Study of Adrenal Tumours

1

2 Corresponding author and person to whom reprint request should be 3 addressed: 4 Prof. Felix Beuschlein, M.D. 5 Klinik für Endokrinologie, Diabetologie und Klinische Ernährung 6 Universitätsspital Zürich 7 Raemistrasse 100, CH-8091 Zürich, Switzerland 8 Phone: +41 44 255 36 25, Fax: +41 44 255 33 30 9 E-mail: felix.beuschlein@usz.ch 10 11 Disclosure statement: J.C. received lecture honoraria from Novartis and 12 educational honoraria from NET connect (funded by Ipsen). M.K. received 13 institutional funding for a clinical trial of cabozantinib in advanced adrenocortical 14 carcinoma from Ipsen. I.B. reports advisory board participation with Corcept and 15 HRA Pharma and consultancy fee with ClinCore outside the submitted work. F.B.C. 16 received honoraria for lecture or consultancy work from Ipsen, Novartis, Bayer, Esai 17 and Novo Nordisk (unrelated to the present topic). S.A. has received lecture 18 honoraria from HRA pharma. J.N.P. has received research and consultancy grants 19 from HRA Pharma, Novartis, Diurnal, Recordati (unrelated to the present topic). M.N. 20 received lecture honoraria from DAIICHI SANKYO Company, Ltd., and Kyowaki rin 21 Co.Ltd. and consultancy grants from Ono Pharmaceutical Co. Ltd., and FUJIF ILM RI

22 Pharma Co.,Ltd. (unrelated to the present topic).

1 **Abstract** (204 words)

2 Adrenocortical carcinoma (ACC) is an orphan disease lacking effective systemic 3 treatment options. The low incidence of the disease and high cost of clinical trials are 4 major obstacles in the search for improved treatment strategies. As a novel approach, 5 registry-based clinical trials have been introduced in clinical research, so allowing for 6 significant cost reduction, but without compromising scientific benefit. Herein, we 7 describe how the European Network for the Study of Adrenal Tumours (ENSAT) 8 could transform its current registry into one fit for a clinical trial infrastructure. The 9 rationale to perform randomized registry-based trials in ACC is outlined including an 10 analysis of relevant limitations and challenges. We summarize a survey on this 11 concept among ENSAT members who expressed a strong interest of the concept 12 and rated its scientific potential as high. Legal aspects, including ethical approval of 13 registry-based randomization were identified as potential obstacles. Finally, we 14 describe three potential randomized registry-based clinical trials in an adjuvant 15 setting and for advanced disease with a high potential to be executed within the 16 framework of an advanced ENSAT registry. Thus we therefore provide the basis for 17 future registry-based trials for ACC patients. This could ultimately provide proof-of-18 principle of how to perform more effective randomized trials for an orphan disease.

1 Introduction

2 Adrenocortical carcinoma (ACC) is a rare disease for which diagnostic approaches 3 and therapeutic strategies have only gradually changed over the past decades (1, 2). 4 Accordingly, the overall survival for patients diagnosed with ACC remains in the 5 range of 3-4 years (3, 4). Affected patients also experience severe morbidity due to 6 endocrine disturbances as well as tumour growth (1, 5, 6). In a recent review, we 7 identified topics including disease prevention and earlier detection, improved risk-8 stratification, controlling tumour growth and invasiveness as well as suppressing 9 hormone production as unresolved problems that need to be addressed by research 10 with the overarching aim to reduce ACC-related morbidity and mortality (1).

11 While clinical trials have the potential to explore strategies to approach these 12 problems, the current research infrastructure fails in providing effective resources to 13 perform such projects on rare diseases. In this context, registry-based clinical trials 14 have emerged as a resource-efficient alternative solution to address clinical and 15 translational research questions (7-10). In this review, we aim to describe how 16 registry-based trials could be used to advance care of patients with ACC. 17 Furthermore, we argue that the European Network for the Study of Adrenal Tumours 18 (ENSAT) is well positioned to transform its current registry and advance its strong 19 collaboration to implement registry-based clinical trials. Finally, we propose potential 20 research projects with potential to be executed within this space.

21

22 Randomized clinical trials

A randomized controlled trial provides the experimental framework that aims to evaluate the effectiveness and safety of a medical intervention. By randomly assigning patients between experimental and control arms, it ensures the greatest reliability and validity of the results, by reducing impact from both known and unrecognized bias. Appropriately executed (11), it is considered as the gold standard for evaluating healthcare interventions. In contrast, those medical practices that are

- 2 -

1 based on evidence from non-randomized controlled data are prone to bias and 2 misinterpretation. Clinical trials lacking a control arm and those using historical 3 controls have repeatedly been shown to exaggerate the efficacy of treatments (12). 4 Similarly, early clinical trials on small or diverse patient samples are prone to find 5 higher response rates than those in subsequent randomized studies (13). Overall, 6 these shortcomings have well been exemplified in a systematic review of >3000 7 randomized clinical studies demonstrating that a total of 396 formerly established 8 medical practices had been identified as lacking clinical benefit (14).

9 While there are a few reported randomized controlled trials on ACC (Table 1), patient 10 scarcity and high resource demand has limited the use of this method. As a 11 consequence, among the 25 recommendations with evidence rating in the recent 12 ACC guidelines by the European Society for Endocrinology and ENSAT, none were 13 considered to have strong underlying evidence and only three were graded as having 14 moderate evidence (5). Currently, there is only one randomized clinical trial active 15 within the space of ACC: Mitotane With or Without Cisplatin and Etoposide After 16 Surgery in Treating Participants With Stage I-III ACC With High Risk of Recurrence 17 (ADIUVO-2, NCT03583710). This study has been designed to be executed within a 18 clinical environment but has yet to be directly integrated into an established patient 19 registry. This sets the stage for further optimization of the clinical trial method for the 20 study of ACC in order to further improve clinical evidence and refine patient care.

21

22 Registry-based clinical trials

A randomized registry-based clinical trial is a prospective study using a clinical registry for patient identification, trial conduct and outcomes reporting. The registrybased randomized clinical trial maintains the strengths of a prospective clinical study, including high internal validity, stringent patient stratification, randomization to ensure unbiased study of interventions and analysing patient outcomes to determine the effect of the studied intervention (7, 9, 15). In variance to conventional trials, registrybased studies provide the opportunity to lower costs and ensure more rapid patient
inclusion (7, 9, 15). This method is particularly suitable for evaluation of interventions
that are already established within the field, with documented data on adverse events
and that does not require additional evaluations than those already performed within
standard clinical practice.

6

A registry structure can be used to identify eligible patients, randomize between different interventions, provide follow-up data and evaluate outcomes. To remain resource-effective, addition of procedures beyond standard clinical practice should be avoided. Experience from cardiovascular research has demonstrated that registry-based clinical studies can be performed with more than 90% cost-saving compared to conventional trials (7, 9). On-going developments of this method include refinements of both biostatistical analysis and interpretation (16).

14

To our knowledge, there are no reported registry-based clinical trials and only a few on-going within the field of medical oncology or endocrinology. In a review by Foroughi and colleagues, on-going registry-based clinical trials were described (9) from which we select two relevant examples:

19 ALT-TRACC (17) is a phase II clinical trial randomizing patients with treatment naïve 20 metastatic colorectal cancer between alternating oxaliplatin and irinotecan doublet 21 schedules (experimental arm) versus continuous doublet chemotherapy (control arm). 22 Primary objective is to evaluate the feasibility of conducting a multi-center, 23 prospective, registry-based randomized clinical trial. The primary endpoint is 24 recruitment rate. Secondary objectives focus on both efficacy and toxicity by 25 collecting data from medical records and other data collection tools. The aim is to 26 estimate progression free survival and radiological response rates. The study is 27 based on the Treatment of Recurrent and Advanced Colorectal Cancer registry (9).

- 4 -

EX-TEM (18) is a phase III trial randomizing patients with newly diagnosed glioblastoma to six (control arm) versus twelve (experimental arm) cycles of postradiation temozolomide chemotherapy. The primary objective is to study treatment efficacy and the primary endpoint is overall survival. Secondary endpoints include adverse events and the necessity for temozolomide dose modification determined by data recorded in the medical records. The study makes usage of *the Brain Registry Australia: Innovation and Translation* registry (9).

8

9 Current and previous randomized trials for ACC

10 An overview of randomized clinical studies on ACC is provided in Table 1. FIRM-ACT 11 was the first randomized study performed on ACC and compared the efficacy of a 12 chemotherapy combination (etoposide, cisplatin and doxorubicin, EDP) plus mitotane 13 versus streptozocin plus mitotane in the advanced setting (19). It reported a hazard 14 ratio of 0.55 (95% Confidence Interval (CI) 0.43-0.69) in favour for EDP plus mitotane 15 for progression free survival. Survival was not significantly different, hazard ratio 0.79 16 (95% CI 0.61-1.02) in favour for EDP + mitotane. Quality of Life according the 17 EORTC QLQ-C30 questionnaire revealed no changes at follow-up compared to 18 baseline for the two treatment arms.

19 As recruitment within the FIRM-ACT protocol had been achieved, it was quickly 20 followed by GALACCTIC, a randomized phase III trial of linsitinib (inhibitor of IGF-1R 21 and the insulin receptor) versus placebo for locally advanced or metastatic ACC (20). 22 No difference in overall survival between linsitinib and placebo was noted, HR 0.94 23 (95% CI 0.61-1.44). This study did, however, provide valuable information on the 24 behaviour of untreated metastatic ACC progressive after mitotane therapy. In the 25 control arm, median survival was 356 days (95% CI 249-556) while the disease 26 control rate was 34.7% (95% CI 21.7–49.6) at 6 weeks and 8.2% at 12 weeks.

There are currently two on-going randomized trials on ACC, both in the adjuvant setting (Table 1), mitotane versus follow-up in low to intermediate risk ACC (ADIUVO study) and mitotane versus mitotane plus cisplatin and etoposide (ADIUVO-2 study)
 in high risk ACC. These trials will be fundamental to evaluate current practices for
 adjuvant therapy that are currently supported by retrospective data (21).

4

5 The European Network for the Study of Adrenal Tumours

6 The European Network for the Study of Adrenal Tumours was formally established in 7 2002 through a merger of three already existing national networks on adrenal 8 research: COMETE in France, GANIMED in Germany, and NISGAT in Italy with 9 further teams joining in from the United Kingdom. In 2009, ENSAT became a 10 membership-based society with statutes and by-laws. An increasing number of 11 researchers and health workers have joined in the efforts of the ENSAT with 12 currently 479 members from 35 different countries. The European Network for the 13 Study of Adrenal Tumours has structured its operation under four different working 14 groups by disease subtype: ACC, pheochromocytoma and paraganglioma, 15 aldosterone-producing adenoma and non-aldosterone producing cortical adrenal 16 adenomas. Through its patient registry, the largest body of clinical annotations and 17 biospecimens from patients with adrenal tumours has been aggregated (22). 18 Currently (April 2020) it includes data from 17,680 patients of 107 institutions, 19 representing 33 predominantly European countries. A long list of disease specific 20 clinical annotations has been collected. Current limitations of the ENSAT registry 21 include its non-consecutive patient enrolment and lack of quality control.

Based on the information reviewed in previous sections, we hypothesized that registry-based trials would be a potential new tool to allow for more efficient studies on adrenal tumours. We hypothesized further that ENSAT would be ideally positioned to implement this technology as it already forms a strong network with large patient populations and operates a prospective registry. Finally, ACC was identified as the most suitable patient population among adrenal tumours to be evaluated in a pilot project due to large unmet needs in combination with up-to-date

- 6 -

clinical practice guidelines and potentially relevant study endpoint already available
 in the registry (5, 23).

3

4 The ENSAT ACC registry

5 Currently, the ACC database includes data from 3,835 patients from 63 institutions 6 (April 2020). It is structured under the following sections; diagnostic procedures (34 7 variables), (20 tumour staging (16 variables), biomaterial variables), 8 chemoembolization (four variables), chemotherapy (seven variables), follow-up (18 9 variables), metabolomics (two variables), mitotane (nine variables), pathology (20 10 variables), radiofrequency (five variables), radiotherapy (eight variables) and surgery 11 (six variables). In total, these comprehensive data can be used to study endpoints 12 relevant for patients with ACC; overall survival, recurrence free survival, progression 13 free survival (accordingly to local analysis, but no specific protocol for radiological 14 evaluation is requested, yet) and early discontinuation of medical therapy. 15 Furthermore, appropriate factors for disease characterization can be used as 16 inclusion / exclusion criteria as well as being incorporated into a future randomization 17 module.

18

19 Assessing the potential for registry-based clinical trials within ENSAT

20 Two online surveys as well as discussions at scientific meetings had been conducted 21 to determine the potential of registry-based clinical trials to be performed within the 22 ENSAT community (Supplementary materials and methods). In a first survey 23 (Supplementary table 1) responses had been collected from eighty-six members, 24 including 66 full members and 20 associate members. The respondents represented 25 22 different countries; Italy (n=22), Germany (n=10), France (n=8), Greece (n=7), 26 United Kingdom (n=7), Netherlands (n=6) and Spain (n=4) being the most frequent. 27 The high interest for registry-based clinical trials in ACC was reflected not only in the 28 active participation in online surveys and real life meetings, but was also expressed directly in the surveys through the rated scientific potential, mean score 4.5
 (maximum 5), and the anticipation to collaborate and contribute, with a mean rating
 of 4.3 (maximum 5).

4 General topics for ENSAT registry-based trials were proposed with positive/negative 5 response options available (Figure 1A); evaluation of drugs or other medical 6 interventions (90% positive), evaluation of prognostic or predictive biomarkers for 7 therapeutic stratification (89% positive), prospective collection of clinical data and/or 8 bio samples (71% positive), and comparison of different follow-up strategies (69% 9 positive). Study participants were also asked, which ACC patient population should 10 primarily be addressed (positive/negative response options available); neo-adjuvant 11 setting (75% positive), adjuvant setting (87% positive) and advanced disease (61% 12 positive). Next, survey participants were asked if they would foresee legal or any 13 other administrative challenges related to registry-based clinical trials, which was 14 answered with yes in 56% of cases with eight free text comments provided. Among 15 these responses, reluctance from ethical review boards to provide ethical 16 permissions were specifically mentioned. Another example demonstrating the strong 17 interest in registry-based clinical trials could be noted in the active discussion of 18 particular scientific projects: There were a total of 48 different research projects being 19 proposed. The ENSAT ACC working group scientific board prioritized these projects 20 based on scientific quality and feasibility for further evaluation.

21 In the subsequent survey (Supplementary table 2) there were 62 respondents, 50 full 22 members and 12 associate members. These represented 19 different countries with 23 Italy (n=19), France (n=6), Germany (n=6), Greece (n=5) and the United Kingdom 24 (n=5) as the most frequent. A total of 87% of responders phrased the expectation 25 that a registry-based clinical trial would be accepted by the local ethical committee, 26 with eight additional comments in free text. In the next question, 43% assumed that 27 randomization of study sites to different interventions ("cluster randomization") would 28 be more likely to be acceptable to ethical review boards compared to randomization

- 8 -

of individual patients. Furthermore, concrete ideas for problems to be addressed
 within an ENSAT registry-based platform were collected.

3

4 **Proposal for registry-based studies on ACC based on the ENSAT platform**

5 Of the 48 different research projects being proposed by the ENSAT ACC working 6 group, the scientific board and its members had previously selected and prioritized 7 the following projects that gained particularly high scoring based on scientific value 8 and feasibility (Figure 1B):

9

Adjuvant setting - Comparison of different durations of mitotane treatment for effectiveness and toxicity. Adjuvant treatment with mitotane is recommended in patients without macroscopic residual tumour after surgery who have a perceived high risk of recurrence (5, 21, 24). However, the optimal duration of mitotane treatment, to balance efficacy and adverse effects of the compound is currently unknown. Therefore, a randomized controlled study between a duration of e.g. 2 vs. 5 years of mitotane treatment would be informative.

17 Advanced ACC I - Comparison of different first-line chemotherapy protocols 18 for effectiveness and toxicity. The most validated first-line treatment option for 19 unresectable and advanced ACC is the combination of etoposide, doxorubicin, 20 cisplatin, and mitotane (EDP-M) (19). Treatment with EDP-M comes with a risk of 21 adverse events. Based on small trials (25, 26) and individual experience (5) it has 22 been hypothesized that omitting doxorubicin from the treatment protocol would 23 increase tolerability without a clinically relevant loss of efficacy. This hypothesis could 24 be evaluated through a randomized controlled study between EDP-M (standard arm) 25 versus etoposide, cisplatin and mitotane (experimental arm).

Advanced ACC II - Comparison of anti-tumour efficacy of mitotane at different concentrations. It is believed that mitotane toxicity and efficacy is strongly correlated to plasma levels of the compound (27-29). It has been hypothesized that

- 9 -

by lowering the therapeutic concentration target for mitotane in advanced ACC, patients would experience less treatment related toxicity. This could potentially result in improved quality of life without clinically significant loss in efficacy. For this purpose, a randomized controlled study between standard therapy aiming at a mitotane blood level > 14 mg/L (standard arm) versus a mitotane regime aiming at lower concentration (e.g. > 10 mg/L; experimental arm) would lead to clinically important information.

8 Potential objectives to be investigated in these three proposals include the evaluation 9 of recruitment feasibility, quality of data capture, patient benefit in terms of overall 10 survival and quality of life as well as drug tolerability. Furthermore, we propose that 11 quality of life could be measured through patient self-reporting through a web-based 12 application (currently not available in the ENSAT registry). In addition, safety could 13 be described from the documentations made in the patient records. We also argue 14 that both cluster and patient randomization could be used to address these three 15 research questions. The studies could also be designed as superiority and/or non-16 superiority trials, all depending on what primary endpoint is finally selected.

17

18 In addition to studying different interventions, we envision the possibility to execute 19 prospective longitudinal observation studies to collect information and biomaterial on 20 predictive markers of treatment response as well as prognostic factors. The 21 underlying rationale comes from the rapid advances in our understanding of the 22 biology of ACC (1, 30-35), which translates into a need for efficient test beds to 23 evaluate new biomarkers for different clinical purposes.

24

25 Challenges

Examples in clinical cardiovascular research has provided a clear proof of concept of how a strong network can be enhanced to perform registry-based clinical trials through technical advances of the current infrastructure but only minor changes in

- 10 -

1 clinical and research practice (7). One potential factor limiting the dissemination of 2 registry-based trials could be legal and administrative restrictions. In our surveys, a 3 high proportion of participants (87%) anticipated acceptance of a registry-based trial 4 by their local ethical review boards. However, as the registry-based randomized trial 5 is a concept currently lacking a clear definition it is expected to be treated with the 6 same level of scrutiny as conventional clinical trials. This will impose rules and 7 regulations not applicable to registry based randomized trials. As such, the current 8 legislative environment needs to be adopted to fit randomized registry-based clinical 9 trials in order to ensure a lower complexity that will otherwise increase costs.

10 While the foundation for a future infrastructure for registry-based trails exist 11 within ENSAT, additional method development will be required including a 12 randomization module as well as the possibility for source data verification (Figure 2). 13 There is also a need for data monitoring to ensure high validity of the data within the 14 registry. Furthermore, our work also raised the potential to implement clinical 15 decision support, active suggestion of potential research studies and integration with 16 patient self-reporting into the ENSAT registry. While such infrastructure upgrades are 17 all technically feasible, additional resources will be necessary for its implementation. 18 And as this research direction is pursued in other medical settings, ENSAT could 19 potentially co-operate with other relevant registries for method development and to 20 share experiences.

21

22 Summary

The ENSAT ACC community has expressed a strong interest and support of in registry-based trials as a new infrastructure with potential to significantly advance care for patients with this rare disease. This review summarises the scientific foundation for this research direction and outlines potential questions to be addressed within such a new infrastructure and provides a roadmap for future pilot projects.

- 11 -

1

2 Acknowledgements

3 We thank Drs. Ivana Kraljevic, Jérôme Bertherat, Christina Pamporaki, Timo 4 Deutschbein, Altieri Barbara, Gregory Kaltsas, Dimitra A Vassiliadi, Boudina Maria, 5 Vincent Montauban, Massimo Mannelli, Gabriella Nesi, Giulia Cantini, Mirko Parasiliti 6 Caprino, Masakatsu Sone, Rebecca Steenaard and Wiebke Arlt for contributing to 7 this project by taking any of the online surveys. The authors also thank Dr. Silviu 8 Sbiera for excellent technical support. J.C. received funding from Region Uppsala, 9 Cancerfonden and Tore Nilsons Stiftelse, F.B. and M.F. were supported by the 10 German Research Foundation (DFG) project number 314061271 (CRC/TRR 205). 11 M.N. received funding from Japan Agency for Medical Research and Development

12 (AMED) (JP19ek0109352).

1 References

 Crona J, Beuschlein F. Adrenocortical carcinoma - towards genomics guided clinical care. Nature reviews Endocrinology. 2019;15(9):548-60.

Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al.
 Adrenocortical carcinoma. Endocrine reviews. 2014;35(2):282-326.
 Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP,

6 3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP,
7 et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the
8 Netherlands since 1993. European journal of cancer (Oxford, England : 1990).
9 2013;49(11):2579-86.

Tella SH, Kommalapati A, Yaturu S, Kebebew E. Predictors of Survival in
 Adrenocortical Carcinoma: An Analysis From the National Cancer Database. J Clin
 Endocrinol Metab. 2018;103(9):3566-73.

5. Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European
Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical
carcinoma in adults, in collaboration with the European Network for the Study of Adrenal
Tumors. Eur J Endocrinol. 2018;179(4):G1-g46.

Steenaard RV, Kremers MNT, Michon LA, Zijlstra M, Haak HR. Patient and Partner
Perspectives on Health-Related Quality of Life in Adrenocortical Carcinoma. Journal of the
Endocrine Society. 2020;4(5):bvaa040.

20 7. James S, Rao SV, Granger CB. Registry-based randomized clinical trials--a new clinical trial paradigm. Nature reviews Cardiology. 2015;12(5):312-6.

8. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European
Unified Registries On Heart Care Evaluation and Randomized Trials. European heart journal.
2019;40(33):2745-9.

Foroughi S, Wong HL, Gately L, Lee M, Simons K, Tie J, et al. Re-inventing the
randomized controlled trial in medical oncology: The registry-based trial. Asia-Pacific journal
of clinical oncology. 2018;14(6):365-73.

Lauer MS, D'Agostino RB, Sr. The randomized registry trial--the next disruptive
 technology in clinical research? N Engl J Med. 2013;369(17):1579-81.

3011.Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for
reporting parallel group randomised trials. BMJ (Clinical research ed). 2010;340:c332.

32 12. Sacks H, Chalmers TC, Smith H, Jr. Randomized versus historical controls for clinical 33 trials. Am J Med. 1982;72(2):233-40.

34 13. Zia MI, Siu LL, Pond GR, Chen EX. Comparison of outcomes of phase II studies and
 35 subsequent randomized control studies using identical chemotherapeutic regimens. J Clin
 36 Oncol. 2005;23(28):6982-91.

- Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, et al. A
 comprehensive review of randomized clinical trials in three medical journals reveals 396
 medical reversals. eLife. 2019;8.
- 40 15. Uppsala Clinical Research Center, <u>https://www.ucr.uu.se/en/services/r-rct</u> Access 41 date 2020-03-09

42 16. Nyberg K, Hedman P. Swedish guidelines for registry-based randomized clinical trials.
43 Upsala journal of medical sciences. 2019;124(1):33-6.

44 17. ALT-TRACC

study,

study.

45 <u>http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12618001480279</u>
 46 Access date 2020-05-01

47 18. EX-TEM

48 <u>http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376473&isReview=true</u>
 49 date 2020-05-01

50 19. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination
51 chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-97.
52 20. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib

52 20. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib 53 (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical 54 carcinoma: a double-blind, randomised, phase 3 study. The lancet oncology. 2015;16(4):426-55 35.

56 21. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. 57 Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-58 80. 1 22. Stell A, Sinnott R. The ENSAT registry: a digital repository supporting adrenal cancer 2 research. Studies in health technology and informatics. 2012;178:207-12.

3 23. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al.
4 Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice
5 Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J
6 Endocrinol. 2016;175(2):G1-g34.

7 24. Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, et al. Long-Term
8 Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical
9 Carcinoma. J Clin Endocrinol Metab. 2017;102(4):1358-65.

10 25. Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, et al. Cytotoxic
11 therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer.
12 1998;78(4):546-9.

13 26. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED. Phase II
14 evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients
15 with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group
16 Study. Cancer. 2000;88(5):1159-65.

Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, et al.
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. J Clin
Endocrinol Metab. 2018;103(4):1686-95.

28. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, et
al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response
to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
J Clin Endocrinol Metab. 2011;96(6):1844-51.

24 29. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, et al. Impact
25 of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of
26 patients with adrenocortical carcinoma. Cancer. 2001;92(6):1385-92.

Assie G, Jouinot A, Fassnacht M, Libe R, Garinet S, Jacob L, et al. Value of
 Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA
 oncology. 2019.

30 31. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated 31 genomic characterization of adrenocortical carcinoma. Nature Genetics. 2014;46(6):607-12.

Schweitzer S, Kunz M, Kurlbaum M, Vey J, Kendl S, Deutschbein T, et al. Plasma
 steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. Eur J Endocrinol.
 2019;180(2):117-25.
 Gara SK, Lack J, Zhang L, Harris E, Cam M, Kebebew E. Metastatic adrenocortical

35 33. Gara SK, Lack J, Zhang L, Harris E, Cam M, Kebebew E. Metastatic adrenocortical
36 carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.
37 Nature communications. 2018;9(1):4172.

38 34. Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, et al. Targeted
 39 Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized
 40 Prognostication. J Clin Endocrinol Metab. 2018;103(12):4511-23.

41 35. Mohan DR, Lerario AM, Else T, Mukherjee B, Almeida MQ, Vinco M, et al. Targeted
42 Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular
43 Subtype of Adrenocortical Carcinoma. Clin Cancer Res. 2019;25(11):3276-88.

44